These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 25951658)
1. Design, synthesis and evaluation of biological activity of novel fasudil analogues. Li H; Wang D; Liu S; Sun C; Chen M; Wang X; Chen L Pharmazie; 2014 Dec; 69(12):867-73. PubMed ID: 25951658 [TBL] [Abstract][Full Text] [Related]
2. The Rho kinase inhibitor fasudil inhibits the migratory behaviour of 95-D lung carcinoma cells. Yang X; Liu Y; Zong Z; Tian D Biomed Pharmacother; 2010 Jan; 64(1):58-62. PubMed ID: 19879105 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of intracellular Ca2+ release by a Rho-kinase inhibitor for the treatment of ischemic damage in primary cultured rat hippocampal neurons. Huang L; Li Q; Li H; He Z; Cheng Z; Chen J; Guo L Eur J Pharmacol; 2009 Jan; 602(2-3):238-44. PubMed ID: 19070614 [TBL] [Abstract][Full Text] [Related]
4. Rho kinase inhibition by fasudil suppresses lipopolysaccharide-induced apoptosis of rat pulmonary microvascular endothelial cells via JNK and p38 MAPK pathway. Liu H; Chen X; Han Y; Li C; Chen P; Su S; Zhang Y; Pan Z Biomed Pharmacother; 2014 Apr; 68(3):267-75. PubMed ID: 24406296 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and pharmacological study of Rho-kinase inhibitors: pharmacomodulations on the lead compound Fasudil. Logé C; Siomboing X; Wallez V; Scalbert E; Bennejean C; Cario-Tourmaniantz C; Loirand G; Gressier B; Pacaud P; Luyckx M J Enzyme Inhib Med Chem; 2003 Apr; 18(2):127-38. PubMed ID: 12943196 [TBL] [Abstract][Full Text] [Related]
6. Design of novel rho kinase inhibitors using energy based pharmacophore modeling, shape-based screening, in silico virtual screening, and biological evaluation. Mishra RK; Alokam R; Singhal SM; Srivathsav G; Sriram D; Kaushik-Basu N; Manvar D; Yogeeswari P J Chem Inf Model; 2014 Oct; 54(10):2876-86. PubMed ID: 25254429 [TBL] [Abstract][Full Text] [Related]
7. Fasudil protects cultured N1E-115 cells against lysophosphatidic acid-induced neurite retraction through inhibition of Rho-kinase. Satoh S; Kawasaki K; Hitomi A; Ikegaki I; Asano T Brain Res Bull; 2011 Feb; 84(2):174-7. PubMed ID: 21126559 [TBL] [Abstract][Full Text] [Related]
8. Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis. Tönges L; Günther R; Suhr M; Jansen J; Balck A; Saal KA; Barski E; Nientied T; Götz AA; Koch JC; Mueller BK; Weishaupt JH; Sereda MW; Hanisch UK; Bähr M; Lingor P Glia; 2014 Feb; 62(2):217-32. PubMed ID: 24311453 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and pharmacological evaluation of novel isoquinoline N-sulphonylhydrazones designed as ROCK inhibitors. Oliveira RG; Guerra FS; Mermelstein CDS; Fernandes PD; Bastos ITS; Costa FN; Barroso RCR; Ferreira FF; Fraga CAM J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1181-1193. PubMed ID: 30044647 [TBL] [Abstract][Full Text] [Related]
10. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses high glucose-induced proliferation and collagen synthesis in rat cardiac fibroblasts. Zhou H; Zhang KX; Li YJ; Guo BY; Wang M; Wang M Clin Exp Pharmacol Physiol; 2011 Jun; 38(6):387-94. PubMed ID: 21457293 [TBL] [Abstract][Full Text] [Related]
11. Rho kinase inhibitor fasudil regulates microglia polarization and function. Zhang H; Li Y; Yu J; Guo M; Meng J; Liu C; Xie Y; Feng L; Xiao B; Ma C Neuroimmunomodulation; 2013; 20(6):313-22. PubMed ID: 23941863 [TBL] [Abstract][Full Text] [Related]
12. Fasudil, a Rho-kinase inhibitor, reverses L-NAME exacerbated severe nephrosclerosis in spontaneously hypertensive rats. Koshikawa S; Nishikimi T; Inaba C; Akimoto K; Matsuoka H J Hypertens; 2008 Sep; 26(9):1837-48. PubMed ID: 18698220 [TBL] [Abstract][Full Text] [Related]
13. [Effects of intervention with Rho kinase inhibitor fasudil on rats with hypoxic pulmonary hypertension]. Sun XZ; Wang DW; Li J Zhonghua Er Ke Za Zhi; 2006 Dec; 44(12):946-7. PubMed ID: 17254468 [No Abstract] [Full Text] [Related]
14. Intraradial administration of fasudil inhibits augmented Rho kinase activity to effectively dilate the spastic radial artery during coronary artery bypass grafting surgery. Takagi T; Okamoto Y; Tomita S; Sato A; Yamaguchi S; Takuwa Y; Watanabe G J Thorac Cardiovasc Surg; 2011 Aug; 142(2):e59-65. PubMed ID: 21397262 [TBL] [Abstract][Full Text] [Related]
15. The Rho kinase inhibitor fasudil is involved in p53-mediated apoptosis in human hepatocellular carcinoma cells. Takeba Y; Matsumoto N; Watanabe M; Takenoshita-Nakaya S; Ohta Y; Kumai T; Takagi M; Koizumi S; Asakura T; Otsubo T Cancer Chemother Pharmacol; 2012 Jun; 69(6):1545-55. PubMed ID: 22481618 [TBL] [Abstract][Full Text] [Related]
16. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses 5-hydroxytryptamine-induced pulmonary artery smooth muscle cell proliferation via JNK and ERK1/2 pathway. Chen XY; Dun JN; Miao QF; Zhang YJ Pharmacology; 2009; 83(2):67-79. PubMed ID: 19052484 [TBL] [Abstract][Full Text] [Related]
17. Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage. Arita R; Hata Y; Nakao S; Kita T; Miura M; Kawahara S; Zandi S; Almulki L; Tayyari F; Shimokawa H; Hafezi-Moghadam A; Ishibashi T Diabetes; 2009 Jan; 58(1):215-26. PubMed ID: 18840783 [TBL] [Abstract][Full Text] [Related]
18. Fasudil, a Rho-kinase inhibitor, attenuates lipopolysaccharide-induced vascular hyperpermeability and colonic muscle relaxation in guinea pigs. Suzuki K; Nemoto K; Ninomiya N; Kuno M; Kubota M; Yokota H J Surg Res; 2012 Nov; 178(1):352-7. PubMed ID: 22487385 [TBL] [Abstract][Full Text] [Related]
19. Rho-kinase inhibitors Y-27632 and fasudil prevent agonist-induced vasospasm in human radial artery. Disli OM; Ozdemir E; Berkan O; Bagcivan I; Durmus N; Parlak A Can J Physiol Pharmacol; 2009 Aug; 87(8):595-601. PubMed ID: 19767883 [TBL] [Abstract][Full Text] [Related]
20. The Rho-kinase inhibitor inhibits proliferation and metastasis of small cell lung cancer. Yang X; Di J; Zhang Y; Zhang S; Lu J; Liu J; Shi W Biomed Pharmacother; 2012 Apr; 66(3):221-7. PubMed ID: 22425182 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]